Home
Clinical Trials
Gemcitabine Hydrochloride or ...

Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Last Updated: 2018-07-23

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

313 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-02-28

Study Completion Date

2018-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pemetrexed disodium and celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving gemcitabine hydrochloride or pemetrexed disodium together with carboplatin is more effective with or without celecoxib in treating non-small cell lung cancer.

PURPOSE: This randomized phase III trial is studying gemcitabine hydrochloride, pemetrexed disodium, and carboplatin to compare how well they work when given together with celecoxib or a placebo in treating patients with advanced non-small cell lung cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma

NCT00101283

Mesothelioma

COMPLETED PHASE2

Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)

NCT00087802

Carcinoma, Non-Small-Cell Lung

COMPLETED PHASE3

Carboplatin and Gemcitabine in Treating Patients With Advanced Solid Tumors

NCT00021346

Unspecified Adult Solid Tumor, Protocol Specific

COMPLETED PHASE1

Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT00022646

Lung Cancer

COMPLETED PHASE2

Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00071136

Lung Neoplasms

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

Primary

* To confirm the beneficial effect of gemcitabine hydrochloride or pemetrexed disodium in combination with carboplatin with or without celecoxib in patients with advanced non-small cell lung cancer that expresses COX-2.

Secondary

* To describe the response rate in patients treated with these regimens.
* To describe the distribution of progression-free survival (PFS) and overall survival of patients treated with these regimens.
* To compare the PFS of patients with COX-2 index ≥ 2 (adjusting for CYP2C9 genotype and celecoxib trough concentrations as covariates) treated with these regimens.
* To correlate urinary PGE-M level with COX-2 expression, COX-2 inhibition, and outcome.
* To evaluate the association between the -765G/C polymorphism in PTGS2 and COX-2 expression in non-small cell lung cancer specimens.
* To characterize a trough plasma celecoxib concentration which will be used as a measure of patient adherence to study treatment and which may be used in future studies for correlations with genotype and pharmacodynamic outcomes.

OUTLINE: This is a multicenter study. Patients are stratified according to gender, disease stage (IIIB vs IV), histology (squamous cell carcinoma vs non-squamous cell carcinoma), smoking status (never/former light smoker \[defined as ≤ 10 pack years AND quit ≥ 1 year ago\] vs smoker), and COX-2 expression status (COX-2 index ≥ 4 vs COX-2 index ≥ 2 but \< 4). Patients are randomized to 1 of 2 treatment arms.

* Arm I: Patients receive gemcitabine hydrochloride\* IV on days 1 and 8 OR pemetrexed disodium\* IV on day 1. Patients also receive carboplatin IV on day 1 and oral celecoxib twice daily on days 1-21.
* Arm II: Patients receive gemcitabine hydrochloride\* OR pemetrexed disodium\* and carboplatin as in arm I. Patients also receive oral placebo twice daily on days 1-21.
* NOTE: \*Patients with squamous cell carcinoma receive gemcitabine hydrochloride; patients with non-squamous cell carcinoma receive pemetrexed disodium.

In both arms, treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, patients with responding or stable disease may continue to receive celecoxib or placebo alone in the absence of disease progression or unacceptable toxicity.

Patients may undergo blood and urine sample collection periodically for correlative laboratory studies.

After completion of study therapy, patients are followed up every 2 months for 2 years and then every 6 months for 3 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm I

Patients receive gemcitabine hydrochloride\* IV on days 1 and 8 OR pemetrexed disodium\* IV on day 1. Patients also receive carboplatin IV on day 1 and oral celecoxib twice daily on days 1-21.

Group Type EXPERIMENTAL

carboplatin

Intervention Type DRUG

Given IV

celecoxib

Intervention Type DRUG

Given orally

gemcitabine hydrochloride

Intervention Type DRUG

Given IV

pemetrexed disodium

Intervention Type DRUG

Given IV

Arm II

Patients receive gemcitabine hydrochloride\* OR pemetrexed disodium\* and carboplatin as in arm I. Patients also receive oral placebo twice daily on days 1-21.

Group Type ACTIVE_COMPARATOR

carboplatin

Intervention Type DRUG

Given IV

gemcitabine hydrochloride

Intervention Type DRUG

Given IV

pemetrexed disodium

Intervention Type DRUG

Given IV

placebo

Intervention Type OTHER

Given orally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

carboplatin

Given IV

Intervention Type DRUG

celecoxib

Given orally

Intervention Type DRUG

gemcitabine hydrochloride

Given IV

Intervention Type DRUG

pemetrexed disodium

Given IV

Intervention Type DRUG

placebo

Given orally

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with stage IV disease are eligible
* Patients with recurrent disease, not amenable to (or refusing) a potentially "curative therapy," are eligible
* Measurable or non-measurable disease

* Measurable disease is defined as lesions that can be accurately measured in ≥ 1 dimension (longest diameter to be recorded) as ≥ 2 cm with conventional techniques or as ≥ 1 cm with spiral CT scan
* Non-measurable disease is defined as all other lesions, including small lesions (longest diameter \< 20 mm with conventional techniques or \< 10 mm with spiral CT scan) and truly nonmeasurable lesions, including any of the following:

* Bone lesions
* Leptomeningeal disease
* Ascites
* Pleural/pericardial effusion
* Inflammatory breast disease
* Lymphangitis cutis/pulmonis
* Abdominal masses that are not confirmed and followed by imaging techniques
* Cystic lesions
* Patients with symptomatic CNS metastases are eligible provided they received prior therapy (e.g., surgery, radiotherapy, or gamma knife), are neurologically stable, and are off steroids for ≥ 14 days before study entry

* Patients with asymptomatic CNS metastases without associated edema, shift, or requirement for steroids or antiseizure medications may be eligible after discussion with the Study Chair
* Patients should be off steroids at least 7 days before preregistration
* No leptomeningeal disease or carcinomatous meningitis

PATIENT CHARACTERISTICS:

* ECOG performance status 0-2
* Granulocytes ≥ 1,500/μL
* Platelet count ≥ 100,000/μL
* Creatinine clearance ≥ 45 mL/min
* Bilirubin ≤ 1.5 mg/dL
* AST and ALT ≤ 2.0 times upper limit of normal (ULN) (≤ 5.0 times ULN if liver metastases are present)
* Serum albumin ≥ 2.5 mg/dL
* Not pregnant or nursing
* Negative pregnancy test
* No "currently active" second malignancy other than non-melanoma skin cancer

* Patients are not considered to have a "currently active" malignancy if they have completed therapy and are considered by their physician to be at \< 30% risk of relapse
* No known hypersensitivity to aspirin, NSAIDs, or sulfonamides
* No active ulcer disease

* No history of gastrointestinal bleeding within the past three years
* None of the following cardiovascular conditions within the past 6 months:

* Myocardial infarction
* Unstable angina
* Symptomatic congestive heart failure
* Serious uncontrolled cardiac arrhythmia
* Cerebrovascular accident or transient ischemic attack
* Pulmonary embolism
* Symptomatic carotid artery or peripheral vascular disease
* Deep vein thrombosis
* Other significant thromboembolic event

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* No prior chemotherapy, immunotherapy, or other systemic therapy for non-small cell lung cancer, including adjuvant therapy
* At least 2 weeks since prior surgery and recovered
* At least 7 days since prior radiotherapy
* At least 14 days since prior NSAIDs (other than low-dose aspirin \[≤ 325 mg daily\]), including any of the following:

* Celecoxib
* Choline Mg
* Trisalicylate (Trilisate®)
* Ibuprofen (Advil® or Motrin®)
* Naproxen (Aleve®, Naprosyn® or Anaprox®)
* Etodolac (Lodine®)
* Oxaprozin (Daypro®)
* Diflunisal (Dolobid®)
* Nabumetone (Relafen®)
* Tolmetin (Tolectin®)
* Valdecoxib (Bextra®)
* No chronic use of NSAIDs (i.e., \> 4 weeks of daily use)

* Patients on low-dose aspirin are eligible
* No other concurrent chemotherapy or hormonal therapy (other than megestrol acetate \[Megace\] for appetite stimulation)
* No other concurrent investigational therapy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Martin J. Edelman, MD

Role: STUDY_CHAIR

University of Maryland Greenebaum Cancer Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Regional Medical Center

Anniston, Alabama, United States

Site Status

Mayo Clinic Scottsdale

Scottsdale, Arizona, United States

Site Status

NEA Medical Clinic - East Matthews

Jonesboro, Arkansas, United States

Site Status

Arkansas Cancer Research Center at University of Arkansas for Medical Sciences

Little Rock, Arkansas, United States

Site Status

City of Hope Comprehensive Cancer Center

Duarte, California, United States

Site Status

Rebecca and John Moores UCSD Cancer Center

La Jolla, California, United States

Site Status

Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center

Los Angeles, California, United States

Site Status

Camino Medical Group - Treatment Center

Mountain View, California, United States

Site Status

Palo Alto Medical Foundation-Camino Division

Mountain View, California, United States

Site Status

Palo Alto Medical Foundation

Palo Alto, California, United States

Site Status

Feather River Hospital Cancer Center

Paradise, California, United States

Site Status

PCR Oncology

Pismo Beach, California, United States

Site Status

Naval Medical Center - San Diego

San Diego, California, United States

Site Status

UCSF Helen Diller Family Comprehensive Cancer Center

San Francisco, California, United States

Site Status

Veterans Affairs Medical Center - San Francisco

San Francisco, California, United States

Site Status

Poudre Valley Hospital

Fort Collins, Colorado, United States

Site Status

Front Range Cancer Specialists

Fort Collins, Colorado, United States

Site Status

Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center

Hartford, Connecticut, United States

Site Status

Middlesex Hospital Cancer Center

Middletown, Connecticut, United States

Site Status

Tunnell Cancer Center at Beebe Medical Center

Lewes, Delaware, United States

Site Status

CCOP - Christiana Care Health Services

Newark, Delaware, United States

Site Status

Washington Cancer Institute at Washington Hospital Center

Washington D.C., District of Columbia, United States

Site Status

Veterans Affairs Medical Center - Washington, DC

Washington D.C., District of Columbia, United States

Site Status

North Broward Medical Center

Deerfield Beach, Florida, United States

Site Status

Florida Hospital - Orlando

Orlando, Florida, United States

Site Status

John B. Amos Cancer Center

Columbus, Georgia, United States

Site Status

Veterans Affairs Medical Center - Atlanta (Decatur)

Decatur, Georgia, United States

Site Status

Dwight David Eisenhower Army Medical Center

Fort Gordon, Georgia, United States

Site Status

Northeast Georgia Medical Center

Gainesville, Georgia, United States

Site Status